Company / Current Liabilities per Share
Lineage Cell Therapeutics, Inc. Current Liabilities per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities per Share
$0.05
FY2025
5-year range
$0.05 / $0.31
FY2021-FY2025
Trend
-35.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities per Share has declined for 4 consecutive years, from $0.31 in FY2021 to $0.05 in FY2025.
Based on SEC 10-K filings.
0.05 in FY2025 with a 5-year CAGR of -0.1%.
Improved from $0.11 to $0.05 over the past 2 years.
Current Liabilities per Share over time
Growth rates
- 3-Year CAGR
- -22.8%
- 5-Year CAGR
- -0.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- Lineage Cell Therapeutics, Inc.'s current liabilities per share has declined for 4 consecutive years.
- In FY2025, current liabilities per share decreased 35.4% year-over-year.
- Peak current liabilities per share was recorded in FY2021.
- Lowest current liabilities per share in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current Liabilities per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.05 | -35.4% |
| FY2024 | $0.08 | -24.4% |
| FY2023 | $0.11 | -5.7% |
| FY2022 | $0.11 | -63.6% |
| FY2021 | $0.31 | +493.4% |
| FY2020 | $0.05 | +1.5% |
| FY2019 | $0.05 | -4.9% |
| FY2018 | $0.05 | -19.8% |
| FY2017 | $0.07 | -31.6% |
| FY2016 | $0.10 | -38.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026